Drug advances in inflammatory bowel disease.
Clin Med (Lond)
; 13(4): 378-82, 2013 Aug.
Article
em En
| MEDLINE
| ID: mdl-23908509
ABSTRACT
The pathogenesis of inflammatory bowel disease (IBD) remains incompletely understood, but is thought to be a consequence of immune dysregulation, impaired mucosal integrity, enteric bacterial dysbiosis and genetic susceptibility factors. Recent drug advances in the treatment of IBD have clarified the role of existing medication, including 5-amino-salicylic acids (5-ASAs) and has seen a burgeoning use of treatment with biologicals. With recent advances in our understanding of these debilitating diseases, it is hoped that novel therapeutic targets can be identified.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Inflamatórias Intestinais
/
Fator de Necrose Tumoral alfa
/
Fatores Imunológicos
/
Anti-Infecciosos
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article